TY - JOUR
T1 - RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics
AU - Salzer, Elisabeth
AU - Cagdas, Deniz
AU - Hons, Miroslav
AU - Mace, Emily M
AU - Garncarz, Wojciech
AU - Petronczki, Özlem Yüce
AU - Platzer, René
AU - Pfajfer, Laurène
AU - Bilic, Ivan
AU - Ban, Sol A
AU - Willmann, Katharina L
AU - Mukherjee, Malini
AU - Supper, Verena
AU - Hsu, Hsiang Ting
AU - Banerjee, Pinaki P
AU - Sinha, Papiya
AU - McClanahan, Fabienne
AU - Zlabinger, Gerhard J
AU - Pickl, Winfried F
AU - Gribben, John G
AU - Stockinger, Hannes
AU - Bennett, Keiryn L
AU - Huppa, Johannes B
AU - Dupré, Loïc
AU - Sanal, Özden
AU - Jäger, Ulrich
AU - Sixt, Michael
AU - Tezcan, Ilhan
AU - Orange, Jordan S
AU - Boztug, Kaan
PY - 2016/12
Y1 - 2016/12
N2 - RASGRP1 is an important guanine nucleotide exchange factor and activator of the RAS-MAPK pathway following T cell antigen receptor (TCR) signaling. The consequences of RASGRP1 mutations in humans are unknown. In a patient with recurrent bacterial and viral infections, born to healthy consanguineous parents, we used homozygosity mapping and exome sequencing to identify a biallelic stop-gain variant in RASGRP1. This variant segregated perfectly with the disease and has not been reported in genetic databases. RASGRP1 deficiency was associated in T cells and B cells with decreased phosphorylation of the extracellular-signal-regulated serine kinase ERK, which was restored following expression of wild-type RASGRP1. RASGRP1 deficiency also resulted in defective proliferation, activation and motility of T cells and B cells. RASGRP1-deficient natural killer (NK) cells exhibited impaired cytotoxicity with defective granule convergence and actin accumulation. Interaction proteomics identified the dynein light chain DYNLL1 as interacting with RASGRP1, which links RASGRP1 to cytoskeletal dynamics. RASGRP1-deficient cells showed decreased activation of the GTPase RhoA. Treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects of RASGRP1-deficient lymphocytes.
AB - RASGRP1 is an important guanine nucleotide exchange factor and activator of the RAS-MAPK pathway following T cell antigen receptor (TCR) signaling. The consequences of RASGRP1 mutations in humans are unknown. In a patient with recurrent bacterial and viral infections, born to healthy consanguineous parents, we used homozygosity mapping and exome sequencing to identify a biallelic stop-gain variant in RASGRP1. This variant segregated perfectly with the disease and has not been reported in genetic databases. RASGRP1 deficiency was associated in T cells and B cells with decreased phosphorylation of the extracellular-signal-regulated serine kinase ERK, which was restored following expression of wild-type RASGRP1. RASGRP1 deficiency also resulted in defective proliferation, activation and motility of T cells and B cells. RASGRP1-deficient natural killer (NK) cells exhibited impaired cytotoxicity with defective granule convergence and actin accumulation. Interaction proteomics identified the dynein light chain DYNLL1 as interacting with RASGRP1, which links RASGRP1 to cytoskeletal dynamics. RASGRP1-deficient cells showed decreased activation of the GTPase RhoA. Treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects of RASGRP1-deficient lymphocytes.
KW - Actins/metabolism
KW - Adolescent
KW - Angiogenesis Inhibitors/pharmacology
KW - B-Lymphocytes/drug effects
KW - Cell Movement/drug effects
KW - Cell Proliferation/genetics
KW - Child
KW - Cytoskeleton/metabolism
KW - Cytotoxicity, Immunologic/genetics
KW - DNA Mutational Analysis
KW - DNA-Binding Proteins/genetics
KW - Dyneins/metabolism
KW - Female
KW - Guanine Nucleotide Exchange Factors/genetics
KW - HEK293 Cells
KW - Humans
KW - Immunoglobulin Class Switching/genetics
KW - Immunologic Deficiency Syndromes/drug therapy
KW - Jurkat Cells
KW - Killer Cells, Natural/drug effects
KW - Lenalidomide
KW - Male
KW - Mutation/genetics
KW - Pedigree
KW - RNA, Small Interfering/genetics
KW - T-Lymphocytes/drug effects
KW - Thalidomide/analogs & derivatives
UR - https://www.scopus.com/pages/publications/84992410702
U2 - 10.1038/ni.3575
DO - 10.1038/ni.3575
M3 - Article
C2 - 27776107
SN - 1529-2908
VL - 17
SP - 1352
EP - 1360
JO - Nature immunology
JF - Nature immunology
IS - 12
ER -